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The ischemic biliary phenotype of hereditary hemorrhagic telan-
giectasia (HHT) is rare but distinct, with progressive biliary tree
ischemia usually resulting in an irreversible secondary sclerosing
cholangiopathy. When clinically severe, liver transplant is often
indicated. We report three patients with marked HHT
associated biliary disease, in whom prolonged anti-vascular
endothelial growth factor therapy (bevacizumab) notably
reversed imaging evidence of biliary disease and clinically obvi-
ated need for liver transplantation during the ﬁrst year of fol-
low-up.
 2013 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal
dominant disorder, characterized by mucocutaneous telangiecta-Journal of Hepatology 20
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C-reactive protein.sias and visceral arteriovenous malformations [1]. Although
radiological signs of liver involvement occur in more than 70%
of patients, less than 10% of these patients develop symptoms
[2]. Symptomatic liver HHT from intrahepatic shunting can lead
to patients presenting with high-output cardiac failure (HOCF),
portal hypertension or ischemic biliary disease [3,4]. A recent
Italian prospective cohort study found that over prolonged fol-
low-up, substantial morbidity and mortality were associated
with liver vascular malformations in HHT patients [5]. The biliary
tree is notably susceptible to ischemia given its dependence on
blood ﬂow from the hepatic artery; ischemic biliary damage is
also a feature of cholangiopathies post-liver transplant (hepatic
artery thrombosis and ischemia-reperfusion injury).
Medical treatments for HHT-related hepatic complications
have been limited [6]. With dysregulated angiogenesis, elevated
plasma concentrations of vascular endothelial growth factor
(VEGF) and transforming growth factor beta [1,7] are seen in
HHT. Bevacizumab, an anti-VEGF antibody, improves anemia
from chronic HHT-related bleeding [8] and high cardiac output
secondary to hepatic vascular malformations (VMs) [9]. We
report three patients with hepatic HHT based on the Curaçao cri-
teria [10], complicated by ischemic cholangiopathy, whose clini-
cal (Table 1) and radiological (Fig. 1) response to bevacizumab
obviated liver transplantation in the ﬁrst year of follow-up.Case report
Patient 1
A 43-year-old woman with newly diagnosed HHT, based on
Curaçao clinical diagnostic criteria (recurrent spontaneous epi-
staxis since childhood, multiple typical mucocutaneous telangi-
ectasias, liver and lung VMs) presented with a 3-month history
of right upper quadrant pain, weight loss, worsening epistaxis,
and melena. The patient’s family history was not immediately13 vol. 59 j 186–189
Table 1. Laboratory ﬁndings before and after therapy.
Patient 1 Patient 2 Patient 3
Parameter Pre Start Post Pre Start Post Pre Start Post
Total bilirubin (<23 µmol/L) 23 100 17 9 17 10 48 73 36
INR (<1.2) 1.4 1.5 1.1 1.1 1.6 1.1 1 1.6 1
Platelets (<400 x 109/L) 418 359 228 221 240 144 148 120 252
ALP (<125 IU/L) 170 320 609 36 85 46 105 486 357
GGT (<78 IU/L) 83 75 167 33 - 71 18 218 328
ALT (<45 IU/L) 19 16 64 19 25 40 34 356 74
AST (<40 IU/L) 21 32 58 26 24 33 52 444 70
Hb (<155 g/L) 68 90 133 106 61 132 151 132 135
CRP (<5 mg/L) - 40 11 4.7 101 3 - 140 5
Pre-treatment values are from 6 months prior, except for patient 2 (two months); post-treatment values are 12 months post initiation of bevacizumab therapy.
INR, international normalized ratio; ALP, alkaline phosphatase; GGT, gamma-glutamyl transferase; ALT, alanine transaminase; AST, aspartate transaminase; Hb,
hemoglobin; CRP, C-reactive protein.
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Fig. 1. Radiologic improvement in biliary disease after treatment with
intravenous anti-vascular endothelial growth factor in patients with hered-
itary hemorrhagic telangiectasia. Contrast-enhanced T1-weighted MRI images
and contrast-enhanced CT image (Patient 2, left column) obtained during the
portal venous phase, before (left column) and after treatment (right column). Pre-
treatment imaging demonstrates dilatation of the intrahepatic ducts (arrows) and
multiple well-deﬁned hypointense/hypodense lesions in keeping with intrahe-
patic bilomas (arrowheads). Peripheral rim enhancement is observed in Patient 3
(left column), suggestive of superimposed infection. Following treatment, there is
resolution of the bilomas and near-complete resolution of the intrahepatic biliary
dilatation (right column). Incidental note made of two hepatic hemangiomas ()
in patient 1.
JOURNAL OF HEPATOLOGYsuggestive of HHT but the family did not come for formal clinical
assessment of HHT. The patient’s genetic testing revealed a vari-
ant in the ACVRL1 gene.
Physical examination revealed cutaneous telangiectasias, a
hyperdynamic heart and hepatic bruit. Laboratory tests
demonstrated anemia (hemoglobin (Hb) 93 g/L, normal range
110–155 g/L; INR 1.5) and cholestasis. Echocardiography
revealed normal left ventricular function and a cardiac index
(CI) of 6.5 L/min/m2 (normal range in women 2.8–3.6 L/min/
m2). Magnetic resonance imaging (MRI) of the liver demonstrated
hepatomegaly (21 cm), markedly dilated arterial vasculature,
typical hepatic telangiectasias, early opaciﬁcation of the hepatic
and portal veins suggestive of arteriosystemic and arterioportal
shunting, and multiple regions of biliary stenosis and dilatation,
attributable to ischemic cholangiopathy. The patient was placed
on a polymeric diet (a liquid diet similar to an elemental diet,
apart from containing intact proteins and complex carbohy-
drates) empirically with the goal of reducing mesenteric steal
post-prandially, as well as ursodeoxycholic acid in conjunction
with regular narcotics due to ongoing, intractable abdominal
pain. Despite an initial improvement, she was readmitted ﬁve
months later with abdominal pain, symptoms of HOCF and severe
anemia. She was febrile with a worsening cholestatic picture and
found to have Enterobacter cloacae bacteremia. Repeat MRI
revealed progression of the intrahepatic biliary strictures, persis-
tent hepatic vascular shunting, and development of large bilo-
mas. Gastroenterology identiﬁed and treated two bleeding
duodenal telangiectatic vessels with argon plasma coagulation,
and the patient was transfused three units of packed red blood
cells within the ﬁrst week of admission. The patient was treated
with intravenous piperacillin-tazobactam for 30 days and then
subsequently oral levoﬂoxacin and metronidazole for 30 days.
The fever was intermittent for three weeks and then resolved.
She was also placed on furosemide to treat her HOCF. In the con-
text of the patient’s complex and worsening HHT manifestations,
she was referred for liver transplantation and concurrently
started on bevacizumab (5 mg/kg administered as an intravenous
infusion) at two-week intervals for a total of six doses, the ﬁrst
two doses given during her admission (at weeks three and ﬁve).
She required two more units of packed red blood cells between
the ﬁrst and second dose of bevacizumab, and then none further.
Her symptoms gradually improved and she was discharged in
stable condition after six weeks in hospital.Journal of Hepatology 201At follow-up, three months after initiation of bevacizumab,
the patient was remarkably clinically improved, with a 7-kg
weight gain, complete resolution of abdominal pain, resolution
of all symptoms of heart failure and no recurrent sepsis. The bil-
irubin and INR had normalized, and the C-reactive protein had
improved signiﬁcantly. Though there was further elevation of
ALP, GGT, AST, and ALT, compared to pretreatment, this was clin-
ically felt to reﬂect the consequences of the severe biliary ische-
mia pretreatment. Epistaxis and gastrointestinal bleeding were
markedly improved and no further blood transfusions were
needed. Cardiac echocardiography revealed a reduction of CI to
3.0 L/min/m2. Liver MRI showed marked diminution of biliary3 vol. 59 j 186–189 187
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dilatation, near resolution of the bilomas, improvement of telan-
giectasias and shunting and normalization of hepatic size and
arterial ﬂow volume (decreased to 0.3 L/min from 1.3 L/min)
(Fig. 1). The patient was continued on a three-monthly mainte-
nance dose of bevacizumab 5 mg/kg for twelve months and
remains well nine months following discharge. Given her excel-
lent response to bevacizumab, she was not listed for liver
transplantation.
Patient 2
A 32-year-old woman with HHT presented with a three-month
history of right upper quadrant pain, weight loss, melena, and
recurrent spontaneous epistaxis. She had a known deﬁnite clini-
cal diagnosis of HHT based on the presence of all four Curaçao cri-
teria (diagnosis of HHT in a ﬁrst degree relative, recurrent
spontaneous epistaxis, multiple typical mucocutaneous telangi-
ectasias and pulmonary VMs) and she had been conﬁrmed to har-
bor the known familial ACVRL1 mutation. Physical examination
revealed a high-ﬂow cardiac murmur, hepatomegaly, and a hepa-
tic bruit. Haematology testing demonstrated anemia (Hb 64 g/L)
requiring transfusion but normal liver biochemistry. Liver MRI
showed hepatic artery dilatation, multiple hepatic telangiectasias
and systemic arteriovenous shunting. In addition, there was
marked segmental intrahepatic biliary dilatation, intraductal ﬁll-
ing defects and multiple bilomas. Phase contrast MRI yielded ﬂow
volumes of 4.0 L/min in the celiac artery (normal <2 L/min).
Despite endoscopic treatment of bleeding gastric telangiectasias,
she required further transfusions and continued to suffer from
paroxysms of pain despite analgesia. She was admitted with
fever, leukocytosis and positive blood cultures for Enterococcus,
which was attributed to cholangitis. Computed tomography dem-
onstrated multiple new bilomas and progression of intrahepatic
biliary dilatation and stricturing. The patient was treated ﬁrst
with piperacillin-tazobactam for 8 days, then changed to
meropenem, and subsequently vancomycin, for ongoing fever,
for another 14 days, with resolution of the fever while on vanco-
mycin. She underwent endoscopic treatment of multiple stomach
angiodysplasias and was transfused in order to maintain a Hb
above 100 g/L, a total of 13 units of packed red blood cells, as well
as receiving 4 units of fresh frozen plasma. Given refractory pain,
anorexia, low-grade gastrointestinal bleeding, anemia, and wors-
ening bilomas, she was started on a course of bevacizumab with
the same regimen as detailed for patient 1. This was started while
she was afebrile on antibiotics and she received the ﬁrst three
doses prior to discharge. She was also referred for assessment
for liver transplantation. After the second dose of bevacizumab,
she required no further transfusions; after the third dose she
was discharged home.
At follow-up, three months following initiation of bev-
acizumab, the abdominal pain, febrile episodes and melena had
resolved. She had gained weight, the severity of epistaxis had
improved and she no longer required blood transfusions. Cardiac
echocardiography showed a normal CI of 2.5 L/min/m2 (from the
elevated 5.3 L/min/m2 pre-bevacizumab). Liver MRI revealed
marked improvement in biliary dilatation, resolution of bilomas,
improvement of telangiectasias and hepatic parenchymal hetero-
geneity and reduction in celiac arterial ﬂow (1.7 L/min) (Fig. 1).
The patient was continued on a maintenance dose of bev-
acizumab as indicated for patient 1. She has regained her weight
and remains asymptomatic one year following discharge from188 Journal of Hepatology 201hospital, with progressive weaning from analgesics, and no pres-
ent indication for liver transplantation.
Patient 3
A 25-year-old woman with HHT was admitted with 6 kg weight
loss, fevers, fatigue and refractory epigastric and right upper
quadrant pain. She had a known deﬁnite clinical diagnosis of
HHT based on the presence of all four Curaçao criteria (diagnosis
of HHT in a ﬁrst degree relative, recurrent spontaneous epistaxis,
multiple typical mucocutaneous telangiectasias and hepatic VMs)
and she had been conﬁrmed to harbor the known familial ACVRL1
mutation. She developed seizures presumed secondary to porto-
systemic shunting and was managed with anti-seizure medica-
tions, ursodeoxycholic acid and lactulose. Physical examination
revealed a hyperdynamic precordium, and a hepatic bruit. Labora-
tory analysis demonstrated cholestasis and Hb 110 g/L. Cardiac
echocardiography showed normal biventricular size and systolic
function but increased CI of 4.6 L/min/m2. Liver MRI demon-
strated marked dilatation of the hepatic artery, diffuse telangiec-
tasias, arteriosystemic venous shunting, irregular intrahepatic
biliary dilatation with areas of focal stricturing, and multiple bilo-
mas. Given the severity of the presentation and complications, the
patient was started on bevacizumab with the same protocol as
detailed for patient 1. She was also assessed for liver transplanta-
tion. She was discharged home after the second dose. At follow-
up, three months after initiation of bevacizumab, the patient’s
weight had stabilized, the pain had improved and there was no
recurrence of hepatic encephalopathy or seizure activity. Cardiac
echocardiography showed a reduction of CI to 3.4 L/min/m2. Lab-
oratory evaluation showed mild elevation of cholestatic liver
enzymes and repeat MRI revealed unchanged biliary dilatation
and bilomas with imaging features indicative of superimposed
infection. Multiple intraductal ﬁlling defects were present, con-
cerning for sloughed biliary epithelium. A focal, likely ischemic
stricturewas also noted in the gallbladder body. Given only partial
improvement after the ﬁrst six doses of bevacizumab, she was
continued on a monthly maintenance dose of bevacizumab for
three months, and then every three months for twelve months.
Whilst listed for liver transplantation, she continued bev-
acizumab, and six months later had an episode of bacterial cho-
langitis, managed with antibiotics and endoscopic intervention.
By 8 months, the patient’s clinical status had signiﬁcantly
improved with resolution of abdominal pain, fatigue and weak-
ness, weight gain and a return to exercise. Her hepatic bruit
resolved and liver enzymes fell, with her CI decreased to 2.9 L/
min/m2. Liver MRI showed near-complete resolution of the bili-
ary ﬁndings with improvement of the arteriosystemic shunting
(Fig. 1). The patient was kept (and continues) on a maintenance
dose of bevacizumab (5 mg/kg) every three months and remains
well one year following her initial presentation, no longer being
listed for liver transplantation.Discussion
We report three patients with HHT, for whom their predominant
clinical presentation was with ischemic cholangiopathy. In these
patients, anti-vascular endothelial growth factor therapy not only
obviated the need for liver transplantation in the ﬁrst year of fol-
low-up, but also resolved biliary features sufﬁciently to be3 vol. 59 j 186–189
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demonstrable radiologically, in a striking manner given that
reversal of biliary disease is rarely reported [11]. Our report
therefore provides helpful, albeit relatively short term, informa-
tion of beneﬁt to patients with HHT and biliary disease, as well
as more broadly to investigators who seek to understand further
mechanisms by which the biliary tree can be damaged by vascu-
lar insufﬁciency. Our patients received therapy without incident,
but remain under active follow-up given the recognized risks of
bevacizumab.
Biliary abnormalities are variably seen in HHT ranging from
26% to 46% of those usually with symptomatic disease [3,4].
Patients are usually female, presenting in the third decade with
symptoms of abdominal/right upper quadrant pain and fatigue,
symptoms related to cholangitis, and/or a cholestatic biochemistry
proﬁle [3,12,13]. The biliary phenotype is believed to arise from
hepatic arterial-venous shunting resulting in stealing/bypassing
of blood from the biliary tree, causing hypoperfusion of the perib-
iliary plexus, bile duct ischemia with subsequent ﬁbrosis, forma-
tion of strictures and focal biliary dilatations. In severe ischemic
injury, biliary necrosis occurswith bile extravasating into the adja-
cent hepatic parenchyma causing bilomas [3,4,12,13], which can
potentially lead to hepatic disintegration [13]. Patterns of biliary
abnormalities related to HHT resemble Caroli’s disease with cystic
dilatations of the intrahepatic bile ducts or sclerosing cholangitis
with irregular, multifocal biliary strictures, sparing the extrahe-
patic ducts [3,4,12]. On imaging, our patients had a dilated com-
mon hepatic artery and extensive hepatic VMs. All patients had
multifocal intrahepatic biliary strictures and bilomas but nor-
mal-appearing extrahepatic bile ducts. Two of our patients had
intraductal ﬁlling defects, likely biliary casts from desquamation
of the ischemic biliary epithelium and intraductal calculi or hem-
orrhage. Liver biochemistry is not necessarily reﬂective of the
degree of biliary injury in the acute setting, and in our series of
patients changes in liver biochemistry became more evident over
time, presumably reﬂecting a degree of biliary damage and repair,
in spite of evident clinical and radiologic improvement.
VEGF is a regulator of angiogenesis and patients with HHT
have elevated plasma concentrations and tissue expression of
VEGF [7]. Anti-VEGF antibodies such as bevacizumab have been
shown to decrease angiogenesis by inhibiting endothelial growth
and simultaneously cause regression of aberrant vessels by pro-
moting endothelial death [14]. We speculate that bevacizumab
by causing regression of existing hepatic capillaries and inhibi-
tion of neovascularization within hepatic arteriovenous malfor-
mations, reduced hepatic arteriovenous shunting in our
patients, thereby reversing arterial steal/peribiliary plexus hypo-
perfusion. Although bevacizumab can have serious side effects,
such as severe hemorrhage, arterial and venous thromboembo-
lism, gastrointestinal perforation, and wound complications, our
patients tolerated the treatment well and did not suffer any com-
plications. To date, liver transplantation for complicated hepatic
HHT remains the only curative option for life-threatening compli-
cations such as ischemic biliary necrosis that fails to respond to
intensive medical therapy. Ischemic cholangiopathy with super-
imposed infection, as was the case in two of our patients, has a
high mortality, and transplantation is difﬁcult in the setting of
uncontrolled systemic sepsis. Procedures, such as transarterial
embolization of hepatic VMs are generally avoided, as they carry
a high risk of hepatic or biliary necrosis, particularly in patients
with biliary presentation of hepatic VMs [6]. Our patients remain
well but naturally longer term outcomes other than thoseJournal of Hepatology 201reported to date, are not yet available, and this limitation to
our observation needs to be acknowledged.
In conclusion, we present three patients with severe biliary
manifestations from HHT who were successfully managed with
intensive medical therapy in the form of prolonged anti-vascular
endothelial growth factor, and for whom clear reversible cholan-
giopathy is evident. This is an important treatment option for
patients to be considered, although further studies are needed
to adequately assess long-term safety, efﬁcacy, as well as wider
applicability of this pharmacologic modality.Conﬂict of interest
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